Preview Mode Links will not work in preview mode

Jan 24, 2020

Pancreatic Cancer Update, Issue 1, 2020 — Our interview with Dr Golan highlights the following topics as well as cases from her practice:

  • Case: A man in his mid-40s with borderline-resectable adenocarcinoma of the pancreas (PAD) receives neoadjuvant FOLFIRINOX (0:00)
  • Indications for adjuvant therapy in patients with borderline-resectable PAD (3:25)
  • Management of borderline-resectable PAD (5:36)
  • Selection of neoadjuvant therapy for patients with pancreatic cancer (8:06)
  • Incidence of BRCA mutations in Israel and the United States (11:51)
  • Case: A woman in her late 70s with node-positive, resectable PAD and multiple comorbidities receives adjuvant gemcitabine/capecitabine (14:03)
  • Dosing and tolerability of gemcitabine/capecitabine as adjuvant therapy for elderly patients (17:36)
  • Perspective on the role of surgical resection for older patients with pancreatic cancer (20:59)
  • Results of the Phase III APACT trial of adjuvant gemcitabine/nab paclitaxel versus gemcitabine alone for surgically resected PAD (23:25)
  • Choice of FOLFIRINOX versus gemcitabine/nab paclitaxel as first-line therapy for mPC (26:35)
  • Reduction in the risk of recurrence with adjuvant therapy (28:38)
  • Perspective on palliative and supportive care for patients with mPC (34:25)
  • Importance of maintaining quality of life and managing depression for patients with pancreatic cancer (40:02)
  • Role of medical marijuana in managing symptoms and treatment side effects in pancreatic cancer (42:56)
  • Single-shot celiac plexus radiosurgery in pancreatic cancer: Palliation and functional outcomes (46:15)
  • Molecular profiling for patients with pancreatic cancer; spectrum of mutations in DNA damage repair genes (48:43)
  • Design, eligibility and endpoints of the Phase III POLO trial evaluating olaparib as maintenance therapy after first-line platinum-based chemotherapy for patients with mPC and a germline BRCA mutation (52:43)
  • POLO trial results and clinical experience with olaparib as maintenance therapy (57:02)
  • Selection and sequencing of therapy for patients with BRCA mutations (59:53)
  • Side effects associated with PARP inhibitors in patients with pancreatic cancer (1:04:51)
  • Response to first-line FOLFIRINOX followed by maintenance olaparib (1:06:44)
  • Novel approaches in the management of pancreatic cancer (1:11:40)

CME information and select publications